Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Current Status of SUMOylation Inhibitors

Author(s): Christopher M. Brackett and Brian S.J. Blagg*

Volume 28 , Issue 20 , 2021

Published on: 10 August, 2020

Page: [3892 - 3912] Pages: 21

DOI: 10.2174/0929867327666200810135039

Price: $65

Abstract

SUMOylation has emerged as an important post-translational modification that involves the covalent attachment of the Small Ubiquitin-like Modifier (SUMO) polypeptide to a lysine residue of a target protein. The enzymatic pathway of SUMOylation is very similar to ubiquitinylation and involves an activating enzyme, a conjugating enzyme, ligases, and deconjugating enzymes. SUMOylation modulates the function of a number of proteins associated with various pathways, and in fact, dysregulation of the SUMOylation pathway is observed in both cancer and neurological diseases. In many cancers, the SUMO enzymes are upregulated, and SUMO levels correlate directly with prognosis and disease progression. As a result, there has been an emphasis on the discovery and development of inhibitors of SUMOylation. In this review, the latest advances in SUMOylation inhibitors are described alongside the methods used to discover small molecule SUMOylation inhibitors, which include natural products, peptidomimetics, as well as synthetic derivatives identified via virtual screens.

Keywords: SUMO, cancer, ubiquitin-like, post-translational modifications, natural products, small-molecules, enzyme inhibitors.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy